These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 20015886)

  • 1. Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemia.
    Deenik W; Janssen JJ; van der Holt B; Verhoef GE; Smit WM; Kersten MJ; Daenen SM; Verdonck LF; Ferrant A; Schattenberg AV; Sonneveld P; van Marwijk Kooy M; Wittebol S; Willemze R; Wijermans PW; Beverloo HB; Löwenberg B; Valk PJ; Ossenkoppele GJ; Cornelissen JJ
    Haematologica; 2010 Jun; 95(6):914-21. PubMed ID: 20015886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia.
    Deenik W; van der Holt B; Verhoef GE; Smit WM; Kersten MJ; Kluin-Nelemans HC; Verdonck LF; Ferrant A; Schattenberg AV; Janssen JJ; Sonneveld P; van Marwijk Kooy M; Wittebol S; Willemze R; Wijermans PW; Westveer PH; Beverloo HB; Valk P; Löwenberg B; Ossenkoppele GJ; Cornelissen JJ
    Blood; 2008 Mar; 111(5):2581-8. PubMed ID: 18172005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose imatinib improves cytogenetic and molecular remissions in patients with pretreated Philadelphia-positive, BCR-ABL-positive chronic phase chronic myeloid leukemia: first results from the randomized CELSG phase III CML 11 "ISTAHIT" study.
    Petzer AL; Wolf D; Fong D; Lion T; Dyagil I; Masliak Z; Bogdanovic A; Griskevicius L; Lejniece S; Goranov S; Gercheva L; Stojanovic A; Peytchev D; Tzvetkov N; Griniute R; Oucheva R; Ulmer H; Kwakkelstein M; Rancati F; Gastl G
    Haematologica; 2010 Jun; 95(6):908-13. PubMed ID: 20145273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Introduction of imatinib as first-line therapy for chronic myeloid leukemia in Cuba.
    Morán VP; Baute RG; Facundo JC; Ramírez PH; Núñez AA; Martínez EE; Cabrera OM; Padrón CH; Otero AG; Uría JC; Estrada EE; Díaz RM; Virgil AM; Sánchez KL; Cabeza AH
    MEDICC Rev; 2011 Jan; 13(1):35-40. PubMed ID: 21273957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Molecular response with triple therapy in patients with chronic myeloid leukemia].
    López-Arroyo JL; Rico-Ramos HJ; Portillo-García ML
    Rev Med Inst Mex Seguro Soc; 2014; 52(3):262-5. PubMed ID: 24878083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results of a prospective phase 2 study combining imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase.
    Gardembas M; Rousselot P; Tulliez M; Vigier M; Buzyn A; Rigal-Huguet F; Legros L; Michallet M; Berthou C; Cheron N; Maloisel F; Mahon FX; Facon T; Berthaud P; Guilhot J; Guilhot F;
    Blood; 2003 Dec; 102(13):4298-305. PubMed ID: 12933584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High rates of durable response are achieved with imatinib after treatment with interferon alpha plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial.
    Guilhot F; Druker B; Larson RA; Gathmann I; So C; Waltzman R; O'Brien SG
    Haematologica; 2009 Dec; 94(12):1669-75. PubMed ID: 19648168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase.
    Kantarjian HM; Cortes J; O'Brien S; Giles FJ; Albitar M; Rios MB; Shan J; Faderl S; Garcia-Manero G; Thomas DA; Resta D; Talpaz M
    Blood; 2002 May; 99(10):3547-53. PubMed ID: 11986206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party.
    Castagnetti F; Palandri F; Amabile M; Testoni N; Luatti S; Soverini S; Iacobucci I; Breccia M; Rege Cambrin G; Stagno F; Specchia G; Galieni P; Iuliano F; Pane F; Saglio G; Alimena G; Martinelli G; Baccarani M; Rosti G;
    Blood; 2009 Apr; 113(15):3428-34. PubMed ID: 19211938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
    Branford S; Rudzki Z; Harper A; Grigg A; Taylor K; Durrant S; Arthur C; Browett P; Schwarer AP; Ma D; Seymour JF; Bradstock K; Joske D; Lynch K; Gathmann I; Hughes TP
    Leukemia; 2003 Dec; 17(12):2401-9. PubMed ID: 14523461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV.
    Hehlmann R; Müller MC; Lauseker M; Hanfstein B; Fabarius A; Schreiber A; Proetel U; Pletsch N; Pfirrmann M; Haferlach C; Schnittger S; Einsele H; Dengler J; Falge C; Kanz L; Neubauer A; Kneba M; Stegelmann F; Pfreundschuh M; Waller CF; Spiekermann K; Baerlocher GM; Ehninger G; Heim D; Heimpel H; Nerl C; Krause SW; Hossfeld DK; Kolb HJ; Hasford J; Saußele S; Hochhaus A
    J Clin Oncol; 2014 Feb; 32(5):415-23. PubMed ID: 24297946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase.
    Quintás-Cardama A; Kantarjian H; Garcia-Manero G; O'Brien S; Faderl S; Ravandi F; Giles F; Thomas D; Wierda W; Cortes J
    Leuk Lymphoma; 2007 Feb; 48(2):283-9. PubMed ID: 17325887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase.
    O'Brien S; Giles F; Talpaz M; Cortes J; Rios MB; Shan J; Thomas D; Andreeff M; Kornblau S; Faderl S; Garcia-Manero G; White K; Mallard S; Freireich E; Kantarjian HM
    Cancer; 2003 Sep; 98(5):888-93. PubMed ID: 12942553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia.
    Preudhomme C; Guilhot J; Nicolini FE; Guerci-Bresler A; Rigal-Huguet F; Maloisel F; Coiteux V; Gardembas M; Berthou C; Vekhoff A; Rea D; Jourdan E; Allard C; Delmer A; Rousselot P; Legros L; Berger M; Corm S; Etienne G; Roche-Lestienne C; Eclache V; Mahon FX; Guilhot F; ;
    N Engl J Med; 2010 Dec; 363(26):2511-21. PubMed ID: 21175313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.
    Hughes TP; Kaeda J; Branford S; Rudzki Z; Hochhaus A; Hensley ML; Gathmann I; Bolton AE; van Hoomissen IC; Goldman JM; Radich JP;
    N Engl J Med; 2003 Oct; 349(15):1423-32. PubMed ID: 14534335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia.
    Kantarjian H; Talpaz M; O'Brien S; Garcia-Manero G; Verstovsek S; Giles F; Rios MB; Shan J; Letvak L; Thomas D; Faderl S; Ferrajoli A; Cortes J
    Blood; 2004 Apr; 103(8):2873-8. PubMed ID: 15070658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imatinib provides durable molecular and cytogenetic responses in a practical setting for both newly diagnosed and previously treated chronic myelogenous leukemia: a study in nagasaki prefecture, Japan.
    Matsuo E; Miyazaki Y; Tsutsumi C; Inoue Y; Yamasaki R; Hata T; Fukushima T; Tsushima H; Imanishi D; Imaizumi Y; Iwanaga M; Sakai M; Ando K; Sawayama Y; Ogawa D; Kawaguchi Y; Nagai K; Tsukasaki K; Ikeda S; Moriuchi Y; Yoshida S; Honda M; Taguchi J; Onimaru Y; Tsuchiya T; Tawara M; Atogami S; Yamamura M; Soda H; Yoshida Y; Matsuo Y; Nonaka H; Joh T; Takasaki Y; Kawasaki C; Momita S; Jinnai I; Kuriyama K; Tomonaga M
    Int J Hematol; 2007 Feb; 85(2):132-9. PubMed ID: 17321991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study.
    Talpaz M; Silver RT; Druker BJ; Goldman JM; Gambacorti-Passerini C; Guilhot F; Schiffer CA; Fischer T; Deininger MW; Lennard AL; Hochhaus A; Ottmann OG; Gratwohl A; Baccarani M; Stone R; Tura S; Mahon FX; Fernandes-Reese S; Gathmann I; Capdeville R; Kantarjian HM; Sawyers CL
    Blood; 2002 Mar; 99(6):1928-37. PubMed ID: 11877262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis.
    de Lavallade H; Apperley JF; Khorashad JS; Milojkovic D; Reid AG; Bua M; Szydlo R; Olavarria E; Kaeda J; Goldman JM; Marin D
    J Clin Oncol; 2008 Jul; 26(20):3358-63. PubMed ID: 18519952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses.
    Kantarjian HM; Cortes JE; O'Brien S; Giles F; Garcia-Manero G; Faderl S; Thomas D; Jeha S; Rios MB; Letvak L; Bochinski K; Arlinghaus R; Talpaz M
    Blood; 2003 Jan; 101(1):97-100. PubMed ID: 12393600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.